Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $3.27 billion. The enterprise value is $2.83 billion.
| Market Cap | 3.27B |
| Enterprise Value | 2.83B |
Important Dates
The last earnings date was Thursday, July 30, 2026, after market close.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 80.39 million shares outstanding. The number of shares has increased by 2.11% in one year.
| Current Share Class | 80.39M |
| Shares Outstanding | 80.39M |
| Shares Change (YoY) | +2.11% |
| Shares Change (QoQ) | +0.92% |
| Owned by Insiders (%) | 0.60% |
| Owned by Institutions (%) | 112.70% |
| Float | 79.88M |
Valuation Ratios
The trailing PE ratio is 29.18 and the forward PE ratio is 22.65.
| PE Ratio | 29.18 |
| Forward PE | 22.65 |
| PS Ratio | 5.82 |
| Forward PS | 5.26 |
| PB Ratio | 2.35 |
| P/TBV Ratio | 6.07 |
| P/FCF Ratio | 19.70 |
| P/OCF Ratio | 18.33 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.89, with an EV/FCF ratio of 17.02.
| EV / Earnings | 24.68 |
| EV / Sales | 5.03 |
| EV / EBITDA | 24.89 |
| EV / EBIT | 30.48 |
| EV / FCF | 17.02 |
Financial Position
The company has a current ratio of 9.16, with a Debt / Equity ratio of 0.03.
| Current Ratio | 9.16 |
| Quick Ratio | 8.60 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.30 |
| Debt / FCF | 0.24 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 8.77% and return on invested capital (ROIC) is 9.69%.
| Return on Equity (ROE) | 8.77% |
| Return on Assets (ROA) | 4.09% |
| Return on Invested Capital (ROIC) | 9.69% |
| Return on Capital Employed (ROCE) | 6.51% |
| Weighted Average Cost of Capital (WACC) | 14.74% |
| Revenue Per Employee | $744,238 |
| Profits Per Employee | $151,633 |
| Employee Count | 755 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 6.19 |
Taxes
In the past 12 months, Veracyte has paid $1.54 million in taxes.
| Income Tax | 1.54M |
| Effective Tax Rate | 1.32% |
Stock Price Statistics
The stock price has increased by +34.61% in the last 52 weeks. The beta is 1.94, so Veracyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.94 |
| 52-Week Price Change | +34.61% |
| 50-Day Moving Average | 52.77 |
| 200-Day Moving Average | 42.43 |
| Relative Strength Index (RSI) | 30.07 |
| Average Volume (20 Days) | 1,332,629 |
Short Selling Information
The latest short interest is 6.86 million, so 8.53% of the outstanding shares have been sold short.
| Short Interest | 6.86M |
| Short Previous Month | 6.67M |
| Short % of Shares Out | 8.53% |
| Short % of Float | 8.59% |
| Short Ratio (days to cover) | 5.50 |
Income Statement
In the last 12 months, Veracyte had revenue of $561.90 million and earned $114.48 million in profits. Earnings per share was $1.39.
| Revenue | 561.90M |
| Gross Profit | 414.44M |
| Operating Income | 92.68M |
| Pretax Income | 116.02M |
| Net Income | 114.48M |
| EBITDA | 113.52M |
| EBIT | 92.68M |
| Earnings Per Share (EPS) | $1.39 |
Balance Sheet
The company has $485.23 million in cash and $40.11 million in debt, with a net cash position of $445.13 million or $5.54 per share.
| Cash & Cash Equivalents | 485.23M |
| Total Debt | 40.11M |
| Net Cash | 445.13M |
| Net Cash Per Share | $5.54 |
| Equity (Book Value) | 1.39B |
| Book Value Per Share | 17.28 |
| Working Capital | 512.04M |
Cash Flow
In the last 12 months, operating cash flow was $178.38 million and capital expenditures -$12.39 million, giving a free cash flow of $165.99 million.
| Operating Cash Flow | 178.38M |
| Capital Expenditures | -12.39M |
| Depreciation & Amortization | 20.83M |
| Net Borrowing | n/a |
| Free Cash Flow | 165.99M |
| FCF Per Share | $2.06 |
Margins
Gross margin is 73.76%, with operating and profit margins of 16.49% and 20.37%.
| Gross Margin | 73.76% |
| Operating Margin | 16.49% |
| Pretax Margin | 20.65% |
| Profit Margin | 20.37% |
| EBITDA Margin | 20.20% |
| EBIT Margin | 16.49% |
| FCF Margin | 29.54% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.11% |
| Shareholder Yield | -2.11% |
| Earnings Yield | 3.50% |
| FCF Yield | 5.08% |
Analyst Forecast
The average price target for Veracyte is $57.82, which is 42.13% higher than the current price. The consensus rating is "Buy".
| Price Target | $57.82 |
| Price Target Difference | 42.13% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 11.92% |
| EPS Growth Forecast (3Y) | 5.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 18.6 and a Piotroski F-Score of 7.
| Altman Z-Score | 18.6 |
| Piotroski F-Score | 7 |